Showing results (121-130 of 290) with videos related to
Sort By:
Pageof 29
The Oncologist|September 30, 2016
Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal CancerAndrew Rankin, Samuel J Klempner, Rachel Erlich, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancerLee M Krug, Christopher G Azzoli, Mark G Kris, et al.Breast Cancer Research and Treatment|October 14, 2015
Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterationsJeffrey S Ross, Siraj M Ali, Kai Wang, et al.Case Reports in Oncology|September 19, 2014
Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown PrimaryNorma A Palma, Siraj M Ali, Jamie O'Connor, et al.Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patientsSai-Hong Ignatius Ou, Leora Horn, Marcelo Cruz, et al.The American Journal of Dermatopathology|January 4, 2017
Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic MelanomaJ Andrew Carlson, Jose Candido Caldeira Xavier, Ashley Tarasen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2011
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinomaMai He, Marzia Capelletti, Khedoudja Nafa, et al.Archives of Pathology & Laboratory Medicine|May 1, 2015
Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment optionsJeffrey S Ross, Sunil Badve, Kai Wang, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2016
Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From GangliogliomaSilviya K Meletath, Dean Pavlick, Tim Brennan, et al.Pediatric Blood & Cancer|January 19, 2017
Identification of NTRK fusions in pediatric mesenchymal tumorsDean Pavlick, Alexa B Schrock, Denise Malicki, et al.Pageof 29